https://www.selleckchem.com/products/erastin.html
Aim To describe real-world treatment patterns/outcomes among patients with HER2+ metastatic breast cancer (MBC). Materials methods Real-world treatments and overall survival (OS) were evaluated among adult women diagnosed with HER2+ MBC, with and without brain metastases (BMs), between June 1, 2012 and May 31, 2018 using electronic medical records from the Definitive Oncology Dataset. Results Among 372 patients, 69% initiated first-line trastuzumab plus pertuzumab-based therapy; many therapy combinations were utilized in the secon
Like
Comment
Share
